Literature DB >> 12676380

Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina.

Edward V Famiglietti1, Edward G Stopa, Edward D McGookin, Philip Song, Victoria LeBlanc, Barbara W Streeten.   

Abstract

In order to establish the cellular and subcellular localization of the chemokine protein, vascular endothelial growth factor (VEGF) or vascular permeability factor, in adult human retina, we employed immunocytochemistry with double immunolabeling, using a primary antibody to amino acids 1-10 of VEGF, together with antibodies to vimentin (intermediate filaments, labeling Müller cells) or to neuron-specific enolase (labeling retinal neurons). In adult human retina, VEGF-like immunoreactivity (VEGF-IR) is found in Müller cell processes, where typically it is found in the cytoplasm in close association with Vimentin-labeled (VM-IR) intermediate filaments. VEGF-IR is sometimes found diffusely in Müller cell bodies and nuclei. VEGF-IR is found in all major classes of retinal neurons, as demonstrated by co-localization with neuron-specific enolase (NSE)-IR, but is especially prominent in cell bodies of amacrine cells (ACs) (including displaced ACs) and ganglion cells (GCs). Generally, VEGF-IR is more prominent in the nucleus, while NSE-IR is more prominent in the cytoplasm and neurites. In blood vessels, VEGF-IR co-localizes with VM-IR, marking blood vessel endothelial cells, whereas NSE-IR apparently marks the layer of smooth muscle cells. These cellular findings regarding the retinal localization of VEGF-IR are consistent with VEGF synthesis in and its export from retinal neurons, particularly amacrine and ganglion cells, as well as in glia, specifically Müller cells, and suggest that retinal neurons normally provide continuous trophic support for their retinal blood supply.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676380     DOI: 10.1016/s0006-8993(02)03766-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

1.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

Review 2.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

3.  Vascular endothelial cell growth factor-a: not just for endothelial cells anymore.

Authors:  Patricia A D'Amore
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 4.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

Review 5.  Involvement of Müller glial cells in epiretinal membrane formation.

Authors:  Andreas Bringmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

Review 6.  The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Authors:  Michael W Stewart
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 7.  Neurovascular cross talk in diabetic retinopathy: Pathophysiological roles and therapeutic implications.

Authors:  Elizabeth P Moran; Zhongxiao Wang; Jing Chen; Przemyslaw Sapieha; Lois E H Smith; Jian-Xing Ma
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-29       Impact factor: 4.733

8.  Effects of anti-VEGF agents on rat retinal Müller glial cells.

Authors:  Bin Guo; Yingli Wang; Yannian Hui; Xinguang Yang; Qinhua Fan
Journal:  Mol Vis       Date:  2010-05-01       Impact factor: 2.367

Review 9.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

10.  CCR3 is a target for age-related macular degeneration diagnosis and therapy.

Authors:  Atsunobu Takeda; Judit Z Baffi; Mark E Kleinman; Won Gil Cho; Miho Nozaki; Kiyoshi Yamada; Hiroki Kaneko; Romulo J C Albuquerque; Sami Dridi; Kuniharu Saito; Brian J Raisler; Steven J Budd; Pete Geisen; Ariel Munitz; Balamurali K Ambati; Martha G Green; Tatsuro Ishibashi; John D Wright; Alison A Humbles; Craig J Gerard; Yuichiro Ogura; Yuzhen Pan; Justine R Smith; Salvatore Grisanti; M Elizabeth Hartnett; Marc E Rothenberg; Jayakrishna Ambati
Journal:  Nature       Date:  2009-06-14       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.